NEW YORK (GenomeWeb) – Illumina today announced agreements with three organizations for use of its next-generation sequencing technologies to develop and run non-invasive prenatal testing in parts of Europe.
Illumina's deals are with Biomnis, which plans to make NIPT available in France; with Genoma for NIPT services in Italy; and with the Center for Human Genetics and Laboratory Diagnostics, which will offer NIPT in Germany.
Under the terms of the agreement, Biomnis, Genoma, and the Center for Human Genetics and Laboratory Diagnostics will use Illumina's HiSeq 2500 platform and consumables to develop their tests. Financial and other terms of the deals were not disclosed.
"These agreements are another step in establishing Illumina as a global leader in reproductive and genetic health solutions and as a valued partner for NGS-based testing across a broad range of clinical applications," Tristan Orpin, Illumina's senior vice president and general manager of Reproductive and Genetic Health, said in a statement.
At the start of the year, Illumina CEO Jay Flatley said at an investor conference that it plans to submit the HiSeq 2500 and Verinata Health's Verifi NIPT for clearance by the US Food and Drug Administration, as Clinical Sequencing News reported.